Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 4.1 (126 reviews) Sold : Login>>
Novo Nosedives on Underwhelming CagriSema Phase III Weight-Loss Data US$ 25.70 Min. order: 1 piece ★★★★★ 4.6 (159 reviews) Sold : Login>>
Novo Nordisk Offers New Contender in Weight Management US$ 26.12 Min. order: 1 piece ★★★★★ 4.1 (14 reviews) Sold : Login>>